NEW YORK (GenomeWeb News) – Sundance Diagnostics today announced an exclusive, worldwide licensing deal with the Max Planck Institute of Psychiatry aimed at developing and commercializing a genetic test for predicting the risk of suicide from use of antidepressants.

Sundance will validate and commercialize the test, which is based on a set of biomarkers discovered by researchers at Max Planck. The Boulder, Colo.-based company plans to launch the test as a laboratory-developed test in the US and Europe and will provide an update on its availability in early 2014.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Researchers find that a personalized medicine approach could help people who experience pain while taking statins, New Scientist reports.

US National Science Foundation is continuing its responsible research conduct training policy despite its flaws, ScienceInsider reports.

A CRISPR-themed meeting explored how the tool could and should be used, Wired reports.

In Science this week: database of proteins' effects on cancer, targeted error correction sequencing, and more.